Positive new data on tiotropium/olodaterol Respimat for COPD

21 May 2015

German family-owned pharma major Boehringer Ingelheim has announced new data analyses from the pivotal Phase III TONADO 1&2 studies. of the once-daily fixed-dose combination of tiotropium + olodaterol Respimat, which was submitted for European and US approval last year (The Pharma Letter July 2, 2014).

The new data showed tiotropium/olodaterol Respimat provided lung function benefit to patients with chronic obstructive pulmonary disease (COPD) right from the start of maintenance therapy, with the greatest benefit shown in the early stages of the disease. These data were presented at the American Thoracic Society Congress 2015 in Denver.

The analyses showed:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK